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The effect of a single dose of ceftazidime on circulating concentrations of interleukin-6 (IL-6) and tumor
necrosis factor alpha (TNF-a) in a rat model of sepsis was studied. IL-6 concentrations were significantly
elevated (100 to 200 times the baseline) 6 h after ceftazidime administration in both septic and nonseptic
(control) rats. TNF-a concentrations increased significantly in nonseptic (;40 times the baseline) rats but not
septic (;2 to 3 times the baseline) rats. Ceftazidime administration was not associated with an increase in
endotoxin concentrations. These findings suggest that ceftazidime modulation of proinflammatory cytokine
concentrations may be independent of its antimicrobial properties.
Sepsis is a diffuse inflammatory disorder that is mediated by
the activity of multiple mediators, including cytokines. Infec-
tions with gram-negative organisms remain the major source of
sepsis because of their virulent nature. Although antimicrobi-
als are the primary treatment options for sepsis, they also have
the potential to worsen the inflammatory state in some patients
(5, 7). This has been attributed to the release of large amounts
of endotoxin (i.e., lipopolysaccharide) as the result of bacterial
killing by bactericidal and cell wall-active antimicrobials (4, 6,
9). Endotoxin is known to enhance the expression of proin-
flammatory cytokines (e.g., tumor necrosis factor alpha [TNF-
a], interleukin-1 [IL-1], and IL-6) that have been implicated in
the pathogenesis of sepsis and multiple-organ-dysfunction syn-
drome (1, 3). Ceftazidime is a third-generation cephalosporin
that has excellent activity against gram-negative aerobic bac-
teria (13). Ceftazidime, however, may increase the concentra-
tion of proinflammatory cytokines, such as TNF-a and IL-6, by
liberating endotoxin from the cell wall of gram-negative bac-
teria (12, 14). Some antimicrobials may also modulate the
function of the immune system by a direct effect on immune
cells and/or the expression of key inflammatory mediators,
including cytokines. Several agents, including some b-lactams,
quinolones, and macrolides, have been found to alter polymor-
phonuclear leukocyte migration and/or phagocytosis, which
may ultimately affect the outcome for infected patients (16).
Additionally, some of these antimicrobials have been shown to
regulate the activity of the cytokine network, independently of
their effects on endotoxin release. The direct effect of ceftazi-
dime on proinflammatory cytokine (e.g., TNF-a and IL-6) ex-
pression in vivo has not been evaluated. In this study, an
animal model of sepsis was used to evaluate the effect of
ceftazidime on circulating concentrations of IL-6 and TNF-a.
The effect of ceftazidime administration on cytokine con-
centrations was evaluated in three groups of rats. Group A was
comprised of rats that had undergone cecal ligation and punc-
ture (CLP) (n 5 6) and group B included healthy rats (n 5 6).
Both groups A and B received ceftazidime. Group C consisted
of rats that underwent CLP surgery (n 5 6) but did not receive
ceftazidime. The effect of ceftazidime administration on endo-
toxin levels was assessed in CLP rats (n 5 3) (group D) and
healthy rats (n 5 3) (group E). All surgical procedures were
performed under aseptic techniques. Healthy rats only under-
went carotid artery and femoral vein cannulation for drug
administration and blood sampling. Ceftazidime was adminis-
tered as a single intravenous bolus (30 mg/kg of body weight)
at time zero. Blood samples (0.25 ml each) were drawn prior to
ceftazidime administration (i.e., at baseline) for the measure-
ment of both cytokines and 3 and 6 h after ceftazidime admin-
istration for TNF-a and IL-6 determinations, respectively. The
amount of blood drawn was replaced with an equal volume of
lactated Ringer’s solution. From the group C rats that did not
receive ceftazidime, a blood sample was drawn 14 h after
surgery for IL-6 and TNF-a determinations. Additional sam-
ples were collected 20 and 17 h after CLP for TNF-a and IL-6
determinations, respectively. Among groups D and E, blood
samples for the measurement of endotoxin concentrations
were drawn before and 6 h after ceftazidime administration.
IL-6 and TNF-a concentrations were measured using rat en-
zyme-linked immunosorbent assay kits. Endotoxin levels were
determined using the chromogenic Limulus amoebocyte lysate
assay. The absolute change (from baseline) in TNF-a and IL-6
concentrations 3 and 6 h after ceftazidime administration, re-
spectively, was compared using a one-way analysis of variance
followed by the Student-Newman-Keuls multiple-comparison
test. An unpaired t test was used to compare the endotoxin
concentrations of CLP and healthy rats treated with ceftazi-
dime. All statistical tests were performed following log trans-
formation of the data, and statistical significance was assumed
when P was #0.05.
The change in systemic concentrations of IL-6 (relative to
baseline) was significantly higher at 6 h after ceftazidime ad-
ministration in the group A and group B rats than in the group
C rats, which did not receive ceftazidime (P , 0.001) (Fig. 1).
TNF-a concentrations at 3 h were also significantly higher in
group B than in group C (P , 0.05) (Fig. 2). Although the
TNF-a concentrations were increased in group A, the increase
did not achieve statistical significance. Low but detectable lev-
els of endotoxin were found in both CLP and healthy rats
before ceftazidime administration, 2.68 6 0.45 and 1.96 6 0.17
endotoxin units (EU)/ml, respectively. The concentration did
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not change significantly after ceftazidime administration in
either group: 2.38 6 0.57 and 1.81 6 1.07 EU/ml (P . 0.05).
Peak serum cytokine concentrations after CLP are generally
lower than those observed after the administration of lipopoly-
saccharide, but they usually remain elevated longer (17). In
this study, CLP was associated with small increments in IL-6
and TNF-a concentrations 14 h after the insult. In contrast, the
concentrations of these cytokines were significantly increased
after ceftazidime administration; IL-6 concentrations were sig-
nificantly elevated 6 h after the administration of ceftazidime
in group A (3,070 6 1,709 pg/ml) and group B (1,245 6 650
pg/ml) rats (Fig. 1). These levels exceeded the concentrations
observed in the control group of rats (group C), which did not
receive ceftazidime, by up to 30-fold. Serum TNF-a concen-
trations also appear to be affected by ceftazidime administra-
tion, although the magnitude of this effect was less than that
seen for IL-6 (Fig. 2). The reason for the different effects of
ceftazidime on IL-6 and TNF-a could be attributed to a dif-
ference in time profiles of the rise and fall of TNF-a and IL-6
concentrations, a more pronounced activity of ceftazidime on
IL-6 biosynthesis, and/or a dysregulation of immune cells that
has been previously observed during the course of sepsis or
after endotoxin treatment of blood in vitro (10, 15). This may
result in a less optimal response mounted against the inflam-
matory trigger by the host than that observed under nonseptic
conditions. Since IL-6 concentrations peak at ;20 h after CLP
(unpublished observations), we measured IL-6 concentration
before administering ceftazidime (i.e., 14 h after surgery), and
6 h thereafter. The time at which serum TNF-a concentrations
peak after surgery or drug administration, however, can be
quite variable and sometimes difficult to detect, since they
decline rapidly after reaching the maximum value. Since
TNF-a concentration elevations usually precede the attain-
ment of IL-6 peak concentrations, we believe that our mea-
sured TNF-a values at 3 h after ceftazidime administration are
representative of but perhaps not precisely the “peak” re-
sponse. Several in vitro and in vivo studies have found that
antimicrobials with high affinity for the penicillin-binding pro-
tein class 3 (PBP 3) have a marked potential to activate cyto-
kine transcription (8, 11). Ceftazidime is known to bind to and
inhibit PBP 3 and therefore may potentially affect the proin-
flammatory cytokine cascade. In this study, the ceftazidime
modulation of cytokine concentrations appears to be endo-
toxin independent. This is suggested by the findings in nonsep-
tic rats (i.e., sham and healthy). In addition, CLP rats that did
not receive ceftazidime did not demonstrate a similar increase
in IL-6, as compared to septic rats treated with ceftazidime.
Since endotoxin concentrations did not change within 6 h after
ceftazidime administration, the effect of ceftazidime on IL-6
and TNF-a in this study is not likely to be due to endotoxin
release. The mechanism of these effects may involve a direct
effect on transcription. Charak and coworkers have suggested
that the myelosuppressive effect of ceftazidime on bone mar-
row progenitor cells is mediated by the release of TNF-a, since
monoclonal antibodies against TNF-a completely inhibited
ceftazidime-induced myelosuppression in vitro (2). This find-
ing supports our hypothesis that ceftazidime administration
modulates the concentration of proinflammatory cytokines in
vivo. Follow-up studies will be needed to evaluate the mecha-
nism(s) and the clinical significance of these observations.
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